source
- With $97M, Latus pursues a different kind of Huntington’s gene therapyThe therapy is part of a plan to develop gene therapies that can be efficiently delivered at lower doses, enabling them to be used against more than just “ultra-rare” conditions.BioPharma Dive · 3mo ago↗ source
- Biotech has a new startup model: Small team, big check and Chinese assetsA new flavor of company is shaking up how biotechs are built. Instead of launching with eye-popping early-stage science or a new platform, there's a surge of startups with small teams, large checks…Endpoints · 3mo ago↗ source
- UCB to acquire maker of antibody treatments for autoimmune diseasesA second shot at gene therapy for Huntington's, China's tightening grip on pharma supply chains, and more Readout biotech updates